Viking Therapeutics, Inc. (VKTX)
33.68
+0.90
(+2.75%)
USD |
NASDAQ |
Sep 01, 16:00
33.65
-0.03
(-0.09%)
After-Hours: 19:41
Viking Therapeutics Total Long Term Debt (Quarterly) : 3.925M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.925M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.318M |
| June 30, 2025 | 0.41M |
| March 31, 2025 | 0.502M |
| December 31, 2024 | 0.63M |
| September 30, 2024 | 0.755M |
| June 30, 2024 | 0.766M |
| March 31, 2024 | 0.852M |
| December 31, 2023 | 0.936M |
| September 30, 2023 | 1.018M |
| June 30, 2023 | 1.10M |
| March 31, 2023 | 1.181M |
| December 31, 2022 | 1.26M |
| September 30, 2022 | 1.337M |
| June 30, 2022 | 1.414M |
| March 31, 2022 | 1.49M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.029M |
| September 30, 2020 | 0.115M |
| June 30, 2020 | 0.198M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.279M |
| December 31, 2019 | 0.36M |
| September 30, 2019 | 0.438M |
| June 30, 2019 | 0.513M |
| March 31, 2019 | 0.588M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 3.721M |
| December 31, 2017 | 3.450M |
| September 30, 2017 | 3.180M |
| June 30, 2017 | 3.050M |
| March 31, 2017 | 3.713M |
| December 31, 2016 | 3.270M |
| September 30, 2016 | 2.826M |
| June 30, 2016 | 2.383M |
| March 31, 2016 | 3.140M |
| December 31, 2015 | 2.152M |
| September 30, 2015 | 4.065M |
| June 30, 2015 | 3.627M |
| March 31, 2015 | 3.272M |
| June 30, 2014 | 1.675M |
| March 31, 2014 | 0.367M |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.978B |
| Eli Lilly & Co. | 49.62B |
| Regeneron Pharmaceuticals, Inc. | 2.707B |
| Skye Bioscience, Inc. | 0.00 |
| Eledon Pharmaceuticals, Inc. | 0.086M |